Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
52,592,482
-
Share change
-
+3,298,029
-
Total reported value
-
$1,490,407,290
-
Put/Call ratio
-
264%
-
Price per share
-
$28.34
-
Number of holders
-
145
-
Value change
-
+$95,537,202
-
Number of buys
-
70
-
Number of sells
-
68
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2020
As of 31 Dec 2020,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
145 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,592,482 shares.
The largest 10 holders included
BlackRock Inc., JPMORGAN CHASE & CO, Essex Woodlands Management, Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, ALLIANCEBERNSTEIN L.P., ArrowMark Colorado Holdings LLC, FMR LLC, Palo Alto Investors LP, and JENNISON ASSOCIATES LLC.
This page lists
146
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.